Cochlear Acquires Demant’s Cochlear Implant Business
Cochlear Limited will support the transition of Oticon Medical's 20,000 cochlear implant customers to the company's technology.
Cochlear Limited will support the transition of Oticon Medical's 20,000 cochlear implant customers to the company's technology.
Sensorion and Cochlear Limited (ASX:COH), announce the initiation of a pilot study of the first-in-class small molecule drug SENS-401 (Arazasetron) in patients scheduled for cochlear implantation.
According to Cochlear, the campaign is supported by 10 hearing health nonprofit and industry partners, and establishes a simple, common metric—defined as 20 decibels in each ear—to help simplify the ongoing conversation and actions related to monitoring hearing health and treating hearing loss, especially among adults 55 years of age and older.
This approval “helps ensure children born deaf have earlier access to a cochlear implant which can provide them with the hearing capabilities to develop speech and language at a trajectory similar to their hearing peers.”
Read MoreAccording to “Reuters,” Cochlear reported underlying profit of A$132.7 million ($88.78 million USD) for the six months ended December 31, slightly above the A$132.1 million it posted a year earlier.
Read MoreCochlear, Ltd cut its full-year profit forecast due to a delay in surgeries at hospitals in China...
Read MoreCochlear Limited (ASX: COH), an implantable hearing solutions company, announced the US Food and...
Read MoreA Pulitzer-Prize nominated reporter has penned Life After Deaf, a new book detailing his...
Read MoreMore than 1,000 Cochlear™ Nucleus® Implant and Baha® System recipients and their families from the United States and Canada will come together at the four-day convention to celebrate the joys, challenges, and personal triumphs of overcoming hearing loss, while improving their hearing performance.
Read MoreThe deepening of this relationship includes joint research and development, shared technology, and strengthened global Smart Hearing Alliance commercial collaboration between Cochlear and GN Hearing, the hearing aid division of the GN Group.
Read MoreA US District Court has awarded $268.1 million in damages against Cochlear Ltd as part of a patent infringement lawsuit filed by the Alfred E. Mann Foundation for Scientific Research and Advanced Bionics LLC.
Read MoreFor this next phase of research and development, a further clinical feasibility study has been initiated to evaluate the totally implantable cochlear implant technology.
Read MoreIn the study, recently published in “Ear and Hearing,” experts have found a correlation between a computer model and the speech intelligibility in implant recipients. This might mean that by improving the performance of the model, the performance of individuals with cochlear implants may benefit in ways that have never before been explored.
Read MoreData from the presented studies showed that SENS-401 protected inner ear function and enhanced sensory hair cell survival in preclinical models of acoustic trauma and, separately, cisplatin infusion.
Read MoreCochlear implant recipients with the Nucleus® 7 Sound Processor can now control their hearing with the Nucleus Smart App from a compatible Android device, which is designed to allow them to monitor and adjust their settings, view personalized hearing information, and even locate a missing sound processor, all from the convenience of their smartphone.
Read MoreThe Cochlear Center for Hearing and Public Health at Johns Hopkins will be a first of its kind at any academic institution, focusing on hearing loss as a global public health priority, and it will be led by one of the preeminent researchers in this area, Frank Lin, MD, PhD. The center will be dedicated to understanding and addressing the impact of hearing loss on public health.
Read MoreThe scholarships, named after two pioneers of the hearing implant industry, recognize Cochlear™ Nucleus® Implant and Baha® System recipients in the United States and Canada who uphold the Cochlear ideals of leadership and humanity, and demonstrate high academic achievement.
Read MoreLim’s work has a strong focus on the improvement of invasive and non-invasive neurostimulation approaches for treating unmet medical needs in hearing and other therapeutic areas.
Read More